Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Experimental and Therapeutic Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-0981 Online ISSN: 1792-1015
Journal Cover
December-2025 Volume 30 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
December-2025 Volume 30 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Discrimination of myelofibrosis and liver cirrhosis using a spleen ultrasound‑based radiomics nomogram model

  • Authors:
    • Si-Chen Chen
    • Yan Ding
    • Xin-Yi Xu
    • Shu-Ying Zhang
  • View Affiliations / Copyright

    Affiliations: Department of Ultrasound Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu 214023, P.R. China, Department of Ultrasound, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China
    Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Article Number: 231
    |
    Published online on: September 25, 2025
       https://doi.org/10.3892/etm.2025.12981
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

The aim of the present study was to develop and validate a spleen ultrasound‑based radiomics nomogram for non‑invasive differentiation between myelofibrosis (MF) and liver cirrhosis. A total of 90 patients (40 patients with MF and 50 with cirrhosis) were enrolled, and randomly divided into training (n=72) and validation (n=18) sets. Ultrasound radiomics features were extracted from spleen images using PyRadiomics, and feature selection was performed using the least absolute shrinkage and selection operator and Boruta algorithms. Multivariate logistic regression combining radiomics features and clinical parameters was used to construct the nomogram model. Two radiomics features (wavelet.HHL_glcm_ClusterShade and original_glszm_GrayLevelNonUniformity) were selected. When combined with direct bilirubin and glutamic‑oxalacetic transaminase levels, the nomogram achieved an area under the curve of 0.958 [95% confidence interval (CI), 0.912‑1.0] in the training set and 0.750 (95% CI, 0.487‑1.0) in the validation set, with sensitivities of 93.8 and 100%, specificities of 87.5 and 60%, and accuracies of 80.3 and 71.4%, respectively. In conclusion, the spleen ultrasound‑based radiomics nomogram demonstrated promising performance for differentiating MF from liver cirrhosis, providing a potential non‑invasive tool for early diagnosis and clinical decision‑making.
View Figures

Figure 1

ROI target volume delineation on
spleen ultrasound images. (A) Original grayscale ultrasound image
showing the maximum long-axis section of an enlarged spleen in a
patient with myelofibrosis. The spleen boundaries are clearly
visible with homogeneous echotexture. (B) The same image with
manual ROI delineation (orange overlay) performed by an experienced
sonographer, encompassing the entire splenic parenchyma while
carefully excluding surrounding structures. The ROI covers 95% of
the visible spleen area, avoiding edge artifacts and adjacent
organs. Scale bar, 5 cm. ROI, region of interest.

Figure 2

Selection of ultrasound radiomics
features. (A) Feature selection of MSE and α value in LASSO
regression. (B) LASSO path. (C) Screen of optimal parameters by
LASSO and Boruta algorithms. LASSO, least absolute shrinkage and
selection operator; MSE, mean squared error.

Figure 3

Clinical-radiomics nomogram for
differentiating MF from liver cirrhosis. To use this nomogram, the
following instructions should be followed: i) Locate the patient's
C2 value on the ‘C2’ axis and draw a vertical line to the ‘Points’
axis to determine the points for this variable; ii) repeat for
glutamic-oxalacetic transaminase and direct bilirubin values; iii)
sum all points and locate this value on the ‘Total points’ axis;
iv) draw a vertical line down to the ‘Risk’ axis to determine the
probability of MF. For example, a patient with C2=1.5,
glutamic-oxalacetic transaminase=30 U/l and direct bilirubin=10
µmol/l would have ~75% probability of MF rather than liver
cirrhosis. MF, myelofibrosis.

Figure 4

Model performance validation and
clinical utility assessment. (A) ROC) curve for the training set
(n=72). The curve demonstrates excellent discrimination with
AUC=0.958 (95% CI, 0.912-1.0). The optimal cutoff point
(sensitivity=93.8%, specificity=87.5%) is marked with a red dot.
(B) ROC curve for the validation set (n=18). The curve shows
moderate discrimination with AUC=0.750 (95% CI, 0.487-1.0),
indicating acceptable but reduced performance compared to the
training set. (C) Calibration curve for the training set. The plot
demonstrates excellent agreement between predicted probabilities
(x-axis) and observed frequencies (y-axis), with the calibration
line closely following the diagonal reference line (perfect
calibration). (D) Calibration curve for the validation set. The
plot shows moderate calibration with some deviation from the
diagonal reference line, particularly at higher predicted
probabilities, suggesting slight model overconfidence in this
cohort. (E) Decision curve analysis for clinical utility
assessment. The graph displays net benefit (y-axis) across
threshold probabilities (x-axis, 0-1.0). The nomogram model (red
line) provides superior clinical utility compared to treat-all
strategy (blue line) or treat-none strategy (black horizontal line
at net benefit=0) for threshold probabilities between 0.1 and 0.8.
ROC, receiver operating characteristic; AUC, area under the curve;
CI, confidence interval.
View References

1 

Lewis SM, Williams A and Eisenbarth SC: Structure and function of the immune system in the spleen. Sci Immunol. 4(eaau6085)2019.PubMed/NCBI View Article : Google Scholar

2 

Garrison RN, McCoy M, Winkler C, Yam L and Fry DE: Splenectomy in hematologic malignancy. Am Surg. 50:428–432. 1984.PubMed/NCBI

3 

Reinert CP, Hinterleitner C, Fritz J, Nikolaou K and Horger M: Diagnosis of diffuse spleen involvement in haematological malignancies using a spleen-to-liver attenuation ratio on contrast-enhanced CT images. Eur Radiol. 29:450–457. 2019.PubMed/NCBI View Article : Google Scholar

4 

Dong HW, Hernandez L, Ghahremani JS, Chapek MA, Safran BA, Lau DL and Brewer MB: Venous stasis ulceration due to massive splenomegaly causing iliac vein compression from secondary myelofibrosis. Vasc Endovascular Surg. 58:769–772. 2024.PubMed/NCBI View Article : Google Scholar

5 

Klimova NF and Glasko EN: Myelofibrosis as one of the masks of liver cirrhosis. Gematol Transfuziol. 28:22–24. 1983.PubMed/NCBI(In Russian).

6 

Lu C, Hu XM, Bao WY, Zhou SY, Fan YQ, Ke J, Wang HS, Zhu RF, Liu Y, Fan L and Xiao SF: Primary biliary cirrhosis secondary to myelofibrosis: A case report and literature review. J Clin Hematol. 31:56–58. 2018.PubMed/NCBI

7 

Lee MW, Yeon SH, Ryu H, Song IC, Lee HJ, Yun HJ, Kim SY, Lee JE, Shin KS and Jo DY: Volumetric splenomegaly in patients with essential thrombocythemia and prefibrotic/early primary myelofibrosis. Int J Hematol. 114:35–43. 2021.PubMed/NCBI View Article : Google Scholar

8 

Gillies RJ, Kinahan PE and Hricak H: Radiomics: Images are more than pictures, they are data. Radiology. 278:563–77. 2016.PubMed/NCBI View Article : Google Scholar

9 

Liu Y, Li C, Guo J and Liu Y: A clinical-radiomics nomogram for differentiating focal organizing pneumonia and lung adenocarcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 44:397–404. 2024.PubMed/NCBI View Article : Google Scholar : (In Chinese).

10 

Breitfeld V and Lee RE: Pathology of the spleen in hematologic disease. Surg Clin North Am. 55:233–51. 1975.PubMed/NCBI View Article : Google Scholar

11 

Barthold D, Brouwer E, Barton LJ, Arterburn DE, Basu A, Courcoulas A, Crawford CL, Fedorka PN, Fischer H, Kim BB, et al: Minimum threshold of bariatric surgical weight loss for initial diabetes remission. Diabetes Care. 45:92–99. 2022.PubMed/NCBI View Article : Google Scholar

12 

Chang TC and Cavuoto KM: Binocular disturbance after glaucoma drainage device implantation. World J Ophthalmol. 4:25–28. 2014.PubMed/NCBI View Article : Google Scholar

13 

Wang X, He TT, Zhang N, Zhou C, Wang Q, Bai YF, Zhang JJ, Fu SG, Liang XX, Li X and Gong M: Clinical characteristics of 12 patients with primary myelofibrosis and liver cirrhosis. J Clin Hepatol. 36:2524–252. 2020.

14 

Li R, Liu HS and Chen Y: Recent research advance to differentiate portal hypertension associated with primary myelofibrosis and cirrhosi. Chin J Exp Hematol. 31:598–601. 2023.PubMed/NCBI View Article : Google Scholar : (In Chinese).

15 

Mazur R, Celmer M, Silicki J, Hołownia D, Pozowski P and Międzybrodzki K: Clinical applications of spleen ultrasound elastography-A review. J Ultrason. 18:37–41. 2018.PubMed/NCBI View Article : Google Scholar

16 

Webb M, Shibolet O, Halpern Z, Nagar M, Amariglio N, Levit S, Steinberg DM, Santo E and Salomon O: Assessment of liver and spleen stiffness in patients with myelofibrosis using fibroscan and shear wave elastography. Ultrasound Q. 31:166–9. 2015.PubMed/NCBI View Article : Google Scholar

17 

Xie QX, Jiang XP and Li X: Clinical characteristic analysis of 17 cases of primary myelofibrosis and portal hypertension. Chin J Infect Dis. 31:369–370. 2013.

18 

Peck-Radosavljevic M: Thrombocytopenia in chronic liver disease. Liver Int. 37:778–793. 2017.PubMed/NCBI View Article : Google Scholar

19 

Yilmaz M and Verstovsek S: Managing patients with myelofibrosis and thrombocytopenia. Expert Rev Hematol. 15:233–241. 2022.PubMed/NCBI View Article : Google Scholar

20 

Ganeshan D, Bhosale P and Kundra V: Current update on cytogenetics, taxonomy, diagnosis, and management of adrenocortical carcinoma: What radiologists should know. AJR Am J Roentgenol. 199:1283–93. 2012.PubMed/NCBI View Article : Google Scholar

21 

Thiele J, Kvasnicka HM, Zankovich R and Diehl V: Early-stage idiopathic (primary) myelofibrosis-Current issues of diagnostic features. Leuk Lymphoma. 43:1035–1041. 2002.PubMed/NCBI View Article : Google Scholar

22 

Lafortune M, Marleau D, Breton G, Viallet A, Lavoie P and Huet PM: Portal venous system measurements in portal hypertension. Radiology. 151:27–30. 1984.PubMed/NCBI View Article : Google Scholar

23 

Johnson SS, Anslyn EV, Graham HV, Mahaffy PR and Ellington AD: Fingerprinting non-terran biosignatures. Astrobiology. 18:915–922. 2018.PubMed/NCBI View Article : Google Scholar

24 

Teodorescu P, Pasca S, Jurj A, Gafencu G, Joelsson JP, Selicean S, Moldovan C, Munteanu R, Onaciu A, Tigu AB, et al: Transforming growth factor β-mediated micromechanics modulates disease progression in primary myelofibrosis. J Cell Mol Med. 24:11100–11110. 2020.PubMed/NCBI View Article : Google Scholar

25 

Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U and Mesa RA: Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 92:289–97. 2014.PubMed/NCBI View Article : Google Scholar

26 

Enke JS, Moltz JH, D'Anastasi M, Kunz WG, Schmidt C, Maurus S, Mühlberg A, Katzmann A, Sühling M, Hahn H, et al: Radiomics features of the spleen as surrogates for CT-based lymphoma diagnosis and subtype differentiation. Cancers (Basel). 4(713)2022.PubMed/NCBI View Article : Google Scholar

27 

Guo L, Liu A, Geng X, Zhao Z, Nie Y, Wang L, Liu D, Li Y, Li Y, Li D, et al: The role of spleen radiomics model for predicting prognosis in esophageal squamous cell carcinoma patients receiving definitive radiotherapy. Thorac Cancer. 15:947–964. 2024.PubMed/NCBI View Article : Google Scholar

28 

Li P, Wu L, Li Z, Li J, Ye W, Shi Z, Xu Z, Zhu C, Ye H, Liu Z and Liang C: Spleen radiomics signature: A potential biomarker for prediction of early and late recurrences of hepatocellular carcinoma after resection. Front Oncol. 11(716849)2021.PubMed/NCBI View Article : Google Scholar

29 

Bolognesi M, Merkel C, Sacerdoti D, Nava V and Gatta A: Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis. 34:144–150. 2002.PubMed/NCBI View Article : Google Scholar

30 

Meng D, Wei Y, Feng X, Kang B, Wang X, Qi J, Zhao X and Zhu Q: CT-based radiomics score can accurately predict esophageal variceal rebleeding in cirrhotic patients. Front Med (Lausanne). 8(745931)2021.PubMed/NCBI View Article : Google Scholar

31 

Kraft WK and Waldman SA: Manufacturer's drug interaction and postmarketing adverse event data: What are appropriate uses? Drug Saf. 24:637–643. 2001.PubMed/NCBI View Article : Google Scholar

32 

Wang FY, Stankiewicz CA, Bennett NL and Myers JS: Hit the ground running: Engaging early-career medical educators in scholarly activity. Acad Med. 94(1837)2019.PubMed/NCBI View Article : Google Scholar

33 

Matsumoto S, Imamura H, Takayanagi A, Fukumitsu R, Goto M, Sunohara T, Fukui N, Omura Y, Akiyama T, Fukuda T, et al: First-in-human trial of center wire for neuroendovascular therapy to avoid guidewire-related complications. Interv Neuroradiol. 31:532–538. 2025.PubMed/NCBI View Article : Google Scholar

34 

Zhao W, Bendickson L and Nilsen-Hamilton M: The lipocalin2 gene is regulated in mammary epithelial cells by NFκB and C/EBP in response to mycoplasma. Sci Rep. 10(7641)2020.PubMed/NCBI View Article : Google Scholar

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Chen S, Ding Y, Xu X and Zhang S: Discrimination of myelofibrosis and liver cirrhosis using a spleen ultrasound‑based radiomics nomogram model. Exp Ther Med 30: 231, 2025.
APA
Chen, S., Ding, Y., Xu, X., & Zhang, S. (2025). Discrimination of myelofibrosis and liver cirrhosis using a spleen ultrasound‑based radiomics nomogram model. Experimental and Therapeutic Medicine, 30, 231. https://doi.org/10.3892/etm.2025.12981
MLA
Chen, S., Ding, Y., Xu, X., Zhang, S."Discrimination of myelofibrosis and liver cirrhosis using a spleen ultrasound‑based radiomics nomogram model". Experimental and Therapeutic Medicine 30.6 (2025): 231.
Chicago
Chen, S., Ding, Y., Xu, X., Zhang, S."Discrimination of myelofibrosis and liver cirrhosis using a spleen ultrasound‑based radiomics nomogram model". Experimental and Therapeutic Medicine 30, no. 6 (2025): 231. https://doi.org/10.3892/etm.2025.12981
Copy and paste a formatted citation
x
Spandidos Publications style
Chen S, Ding Y, Xu X and Zhang S: Discrimination of myelofibrosis and liver cirrhosis using a spleen ultrasound‑based radiomics nomogram model. Exp Ther Med 30: 231, 2025.
APA
Chen, S., Ding, Y., Xu, X., & Zhang, S. (2025). Discrimination of myelofibrosis and liver cirrhosis using a spleen ultrasound‑based radiomics nomogram model. Experimental and Therapeutic Medicine, 30, 231. https://doi.org/10.3892/etm.2025.12981
MLA
Chen, S., Ding, Y., Xu, X., Zhang, S."Discrimination of myelofibrosis and liver cirrhosis using a spleen ultrasound‑based radiomics nomogram model". Experimental and Therapeutic Medicine 30.6 (2025): 231.
Chicago
Chen, S., Ding, Y., Xu, X., Zhang, S."Discrimination of myelofibrosis and liver cirrhosis using a spleen ultrasound‑based radiomics nomogram model". Experimental and Therapeutic Medicine 30, no. 6 (2025): 231. https://doi.org/10.3892/etm.2025.12981
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team